ICPT

ICPT Articles

We screened our 24/7 Wall St. research database for hot biotech ideas and found four companies that are offering big upside for aggressive accounts. All are rated Buy and have the potential to...
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
These four momentum biotech plays still have solid upside to the Jefferies price targets and would be solid additions to aggressive accounts with higher risk tolerance.
Windstream, Uniti Group, Intercept Pharmaceuticals, and Genocea Biosciences all posted new 52-week lows on Wednesday.
Versartis, Intercept Pharma, Kroger, and Mattel all posted new 52-week lows on Friday.
Kroger, Bed Bath & Beyond, Intercept Pharmaceuticals, and Mattel all posted new 52-week lows on Thursday.
As we have said before, updates from the FDA have the potential to make or break a company. In this case it seems like a mild setback, but further complications could prove to be catastrophic.
The top analyst upgrades, downgrades and other research calls from Wednesday include Biogen, Electronic Arts, Gap, Intuit, Johnson & Johnson, 3M, Intercept Pharmaceutical and AutoZone.
HP Enterprise, Discovery Communications, Intercept Technologies, and Advaxis all posted new 52-week lows on Tuesday.
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
Friday’s top analyst upgrades, downgrades and initiations include Apache, Baker Hughes, Jack in the Box, Rite Aid, Synchrony Financial and U.S. Steel.
Friday's top analyst calls include Alibaba, Amazon, Bank of America, Cypress Semiconductor, Flextronics, JC Penney, Lululemon Athletica and Microsoft.
Intercept Pharmaceuticals announced that the FDA has extended the PDUFA date for its Priority Review of obeticholic acid in primary biliary cholangitis.